ModifiedUnitedHealthcarePolicy CSNCT0407.04

Intensity-Modulated Radiation Therapy (for North Carolina Only)

Policy governing coverage and medical necessity criteria for intensity-modulated radiation therapy for individuals 19 years and older in North Carolina; applies to clinical indications, coding, and documentation requirements.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for North Carolina Only)

Policy CodePolicy CSNCT0407.04

Change TypeCoverage criteria revised (material)

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionWhen requesting IMRT for indications not listed as proven, submit prior authorization with comparison treatment plans and documentation showing clinially meaningful OAR dose reduction or prior irradiation requiring sculpted dosing.

SourceLink

POLICY UPDATE CHANGES

Revised list of conditions for which IMRT for Definitive Therapy is proven and medically necessary; added 'vulvar cancer' and replaced 'anal cancer' with 'anus/anal canal cancer'.

Created state-specific policy version for the state of North Carolina (no change to coverage guidelines).

Added language that this Medical Policy does not apply to the states of Idaho and Kansas; refer to the state-specific policy versions.

Added language that medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage.

Updated definition of 'Definitive Therapy'.

NCjurisdiction governed

19+

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

inv-01: Proven/Covered Indications

Covered when ALL of the following proven indications apply for definitive therapy of the primary site:

Proven/Covered Indications: IMRT for Definitive Therapy of the primary site for: anus/anal canal; breast cancer when left-sided internal mammary nodes are treated or accelerated partial-breast irradiation (APBI) up to 5 fractions; central nervous system tumors (brain, brainstem, spinal cord), including benign CNS tumors; cervical cancer; endometrial cancer; esophageal cancer; head and neck cancers (including lymphoma and solitary plasmacytoma when treatment includes pharynx, larynx [stage III–IV glottic], salivary glands, oral cavity, nasal cavity, paranasal sinuses); mediastinal tumors (e.g., lymphomas, thymomas), including tracheal cancer; non-small cell lung cancer stage III undergoing chemoradiation; pancreatic cancer; prostate cancer; vulvar cancer; compensator-based beam modulation when performed in combination with a proven IMRT indication listed above; and hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) up to 10 fractions for brain metastasis (with accompanying eligibility criteria).

List extracted verbatim from policy

inv-02: Case-by-case Exceptions

Considered (case-by-case) when at least ONE of the following is present:

Case-by-case Exceptions: 1) A condition not listed as proven where using a clinically appropriate non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity, demonstrated by comparison treatment plans (e.g., per RTOG or QUANTEC); 2) The same or an immediately adjacent area has been previously irradiated and sculpting the dose distribution is required to avoid exceeding cumulative normal tissue tolerance.

Requests evaluated case-by-case; documentation should include comparative planning

inv-03: Unproven / Not Medically Necessary

Not medically necessary for:

Unproven / Not Medically Necessary: Use of IMRT in conjunction with proton beam radiation therapy — considered unproven and not medically necessary due to insufficient evidence of efficacy.

Policy statement

inv-04: Supported indications and rationale

Evidence and guideline–backed scenarios where IMRT is supported:

Anal cancer - DP-IMRT evidence: Dose-painted IMRT (DP-IMRT) with concurrent 5FU/MMC (RTOG 0529) demonstrated significant reductions in acute grade 2+ hematologic events and grade 3+ GI and dermatologic toxicity and comparable long-term efficacy to conventional radiation, supporting DP-IMRT use with appropriate RT QA and staging for T2-4N0-3M0 anal cancer.

Phase II trial findings and long-term follow-up

Breast cancer - APBI-IMRT: APBI delivered with IMRT (30 Gy in 5 fractions) in selected low-risk early breast cancer resulted in low 10-year ipsilateral recurrence and significantly less acute and late toxicity and improved cosmesis versus whole-breast irradiation (Florence trial).

Phase III randomized trial, median follow-up 10.7 years

Breast cancer - left-sided with DIBH: IMRT with deep inspiration breath hold reduced cardiac and pulmonary doses versus standard 3D-CRT when internal mammary nodes are targeted and may preserve left ventricular ejection fraction in selected left-sided patients.

Small randomized trial evidence

inv-05: Gynecologic cancer recommendations

Clinical guidance and evidence-based recommendations summarized from professional guidelines and trials:

Gynecologic cancers (postoperative and definitive): Guidelines (ASTRO, ESGO/ESTRO/ESP, NCCN) recommend IMRT to decrease acute and late GI and GU toxicity for postoperative pelvic RT and conditionally recommend IMRT for definitive pelvic RT; IGRT is recommended to ensure safe delivery and margin reduction.

Supported by randomized and comparative studies and guideline statements

inv-06: Esophageal cancer recommendations

Esophageal cancer context and recommendations:

Esophageal cancer: IMRT may be used in preoperative, definitive, and postoperative settings when reduction in heart and lung dose is required; dosimetric comparisons and a meta-analysis report lower irradiated heart and lung volumes with IMRT and some analyses report improved overall survival versus 3D-CRT.

NCCN supports IMRT or proton therapy when OAR dose reduction is necessary

inv-07: Glioblastoma (head/brain) findings

Glioblastoma / head & brain findings (limited retrospective evidence):

Glioblastoma: Single-center retrospective comparisons show no significant difference in overall or progression-free survival between IMRT and 3D-CRT; IMRT may be associated with fewer out-of-field recurrences in some subgroups but evidence is limited and heterogeneous.

Interpret cautiously due to retrospective design and small samples

inv-08: Covered Indications / Rationale

Covered when care aligns with guideline-supported indications and documented clinical rationale:

Head and neck cancers - IMRT preferred: Use of IMRT is supported to reduce long-term toxicity (e.g., xerostomia, dysphagia) and is preferred by NCCN for oropharyngeal, nasopharyngeal, nasal cavity, paranasal sinus, salivary gland, and thyroid cancers; DO-IMRT or parotid-sparing IMRT have randomized evidence for reduced xerostomia and improved swallowing outcomes.

Randomized trials show reduced xerostomia and improved patient-reported outcomes

HA-WBRT with memantine for brain metastases: HA-WBRT plus memantine is recommended for patients receiving WBRT who have no metastases in the hippocampal-avoidance region and expected survival ≥ 4 months to preserve cognitive function; phase III randomized data (n=518) showed reduced cognitive failure without differences in OS or intracranial PFS.expected survival >= 4 months; absence of hippocampal lesions

Brown et al. phase III trial and ASCO/SNO/ASTRO and NCCN recommendations

inv-09: HA-WBRT (hippocampal avoidance)

HA-WBRT (hippocampal avoidance) coverage considerations:

HA-WBRT with memantine considered standard: HA-WBRT plus memantine preserves cognitive function versus WBRT plus memantine for eligible patients (no hippocampal lesions, expected survival ≥4 months) and is recommended by ASCO/SNO/ASTRO and preferred by NCCN for patients with better prognosis; NCCN specifies no metastases within 5 mm of the hippocampus and dosing of 30 Gy in 10 fractions in preferred candidates.no metastases within 5 mm of the hippocampus; expected survival >= 4 months; up to 10 fractions

Phase III trial (Brown et al.) demonstrated reduced cognitive failure

inv-10: Mediastinal tumors / lymphoma / thymic tumors

Mediastinal disease coverage considerations and rationale:

Mediastinal tumors / lymphoma / thymic tumors: IMRT can improve conformity and reduce high-dose exposure to heart, esophagus, and spinal cord compared with APPA/3D-CRT and is appropriate when planning demonstrates reduced OAR doses or improved PTV coverage; consider potential increased low-dose exposure to breasts and long-term secondary malignancy risk when selecting technique.

Systematic reviews and institutional series report improved conformity and reduced high-dose OAR volumes; adhere to dose constraints

inv-11: NSCLC stage III

Stage III non–small cell lung cancer coverage considerations:

NSCLC stage III: IMRT is preferred over 3D-CRT for stage III NSCLC treated with concurrent chemoradiation because it is associated with lower heart doses, reduced rates of grade ≥3 pneumonitis, and similar survival and tumor-control outcomes; minimizing heart dose metrics (e.g., V40, V50) is associated with improved outcomes.

RTOG 0617 secondary analyses and NCCN statements support IMRT preference

inv-12: Pancreatic cancer

Pancreatic cancer coverage considerations and evidence summary:

Pancreatic cancer: IMRT may reduce acute and late gastrointestinal toxicity versus 3D-CRT while maintaining equivalent OS and PFS in locally advanced pancreatic cancer; ASTRO guidelines strongly recommend modulated techniques for localized pancreatic cancer and NCCN supports IMRT among acceptable techniques to improve PTV coverage and spare OARs.

Single-center studies and systematic reviews report lower GI toxicity with IMRT

inv-13: Prostate cancer

Prostate cancer coverage considerations:

Prostate cancer: IMRT is an appropriate technique for prostate cancer with guideline support (AUA/ASTRO, NCCN); dose-escalated and moderately hypofractionated IMRT regimens provide acceptable tumor control with reduced acute and late GI/GU toxicity versus 3D-CRT in many studies; counsel patients about transient QOL worsening at RT end with recovery by six months for most domains.

Prospective observational and randomized trial data support toxicity and QOL findings

inv-14: Clinical evidence and guideline recommendations

Cross–site clinical evidence and guideline recommendations relevant to IMRT use:

Pancreas/prostate/vulvar and combined statements: Guidelines and trials across tumor sites indicate IMRT improves PTV coverage and reduces dose to OARs; multiple society guidelines (NCCN, ASTRO, AUA, ESGO) endorse IMRT or other advanced techniques when OAR sparing is clinically relevant. No evidence supports combining IMRT and proton beam radiotherapy in a single plan.

Guideline-based statements and document combined-therapy exclusion

inv-15: Revised Definitive Therapy Indications

Policy history and revision note:

Revised definitive therapy indications: Policy revised the definitive therapy indications: added 'vulvar cancer' and replaced 'anal cancer' with 'anus/anal canal cancer' in the list of proven and medically necessary primary-site indications for IMRT.

See Policy History for details

The policy states that the combined use of IMRT with proton beam radiation therapy is considered unproven and not medically necessary due to insufficient evidence of efficacy. This applies to IMRT delivered in conjunction with proton-beam RT rather than sequential or separate-course therapy.

The provided excerpts do not list additional explicit exclusions beyond those described elsewhere in the policy. Requests for indications not listed as proven are evaluated on a case-by-case basis with required supporting documentation (e.g., comparative treatment plans) rather than by a prespecified exclusion list.

For intact cervical cancer, IMRT should not be used as a routine alternative to brachytherapy for central disease. NCCN guidance emphasizes that IMRT can reduce pelvic/ bowel dose for definitive or postoperative pelvic radiation, but brachytherapy remains the standard for central intact cervix disease and IMRT is not a substitute.

Candidates for hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) must have no metastases within the hippocampal-avoidance region; the presence of hippocampal lesions excludes candidacy per guideline recommendations. Additionally, patients with poor performance status (e.g., low KPS/ECOG thresholds cited in guidelines) are not considered appropriate candidates for HA-WBRT.

Guideline-based eligibility for HA-WBRT requires an expected survival of at least 4 months. Individuals with an expected survival of 4 months are not considered appropriate candidates for hippocampal-avoidance WBRT according to ASCO/SNO/ASTRO and related guidance.

No clinical evidence was identified supporting delivery of combined IMRT and proton beam radiotherapy in a single treatment plan. The policy therefore does not support combined-single-plan approaches and notes the lack of supporting literature for such plans.

This Medical Policy version is state-specific and explicitly does not apply to Idaho and Kansas; providers should refer to the applicable state-specific policy versions for those states when determining coverage.

The policy reiterates that use of IMRT in conjunction with proton beam therapy is considered not medically necessary because the available evidence is insufficient to demonstrate efficacy for combined delivery approaches.

The excerpts do not present a comprehensive list of services labeled explicitly as "not medically necessary" beyond the IMRT‑plus‑proton statement; instead, comparative evidence and guideline summaries are used to support the contexts in which IMRT is appropriate or unsupported. Coverage determinations rely on the documented clinical rationale and the cited comparative evidence rather than blanket exclusions in these sections.

Across several tumor sites, the evidence demonstrates that IMRT primarily reduces normal‑tissue toxicity but does not consistently improve overall survival or locoregional control compared with 3D‑CRT. Therefore IMRT’s principal demonstrated benefit is toxicity reduction and organ sparing rather than survival advantage in many contexts.

Randomized trial data in unresectable stage III NSCLC (RTOG 0617) showed that escalation to 74 Gy with concurrent chemotherapy was not superior to standard‑dose (60 Gy) therapy and may be harmful; high‑dose RT outside guideline‑supported regimens is not supported by the cited evidence.

The policy history excerpts provided do not contain additional explicit not medically necessary declarations beyond those already summarized; these policy‑history notes record revisions to covered indications and administrative clarifications rather than new blanket denials.

Billing, Code Sets, and Dosimetric Limits

Applicable CPT/HCPCS codesmixed

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple.
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.

Additional HCPCS codesHCPCS

G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session.
G6017	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment.

FDA product codesmixed

MUJ	FDA product code referenced for IMRT devices
IYE	FDA product code referenced for IMRT devices

HA-WBRT fraction limit — key numeric limit

HA-WBRT fraction limitUp to 10 fractions

IndicationHippocampal-avoidance WBRT for brain metastasis

Concurrent medication recommendedTypically delivered with memantine per guideline recommendations

Hippocampus exclusion distance — hippocampal avoidance planning constraint

Hippocampus exclusion distanceNo metastases within 5 mm of the hippocampus

Leptomeningeal diseaseHA-WBRT not preferred if leptomeningeal disease present (NCCN guidance)

Prior Authorization, Documentation, and Delivery Expectations

Prior Authorization

Prior authorization & guideline‑aligned justification recommended

Prior authorization is recommended for indications not explicitly listed as proven. When requesting IMRT (including hippocampal-avoidance WBRT), provide guideline-aligned justification that cites relevant clinical practice guidelines (e.g., NCCN, ASTRO, ASCO/SNO, ACR, ESMO) and explains the clinical rationale for selecting IMRT over non‑IMRT techniques. Include documentation showing that IMRT is expected to reduce dose to critical organs-at-risk (OARs) or otherwise materially reduce the probability of clinically meaningful normal tissue toxicity when compared with an appropriate non-IMRT plan (for example, a 3D‑CRT plan).

Provide copies of both the IMRT plan and a comparison non-IMRT plan (e.g., 3D‑CRT) demonstrating dosimetric advantage when IMRT is requested for a non-listed indication.
Cite specific guideline recommendations and rationale supporting IMRT use for the clinical scenario (e.g., NCCN preference for IMRT in head & neck, pelvic postoperative/definitive RT, para‑aortic nodes; ASTRO/ASCO/SNO guidance for HA‑WBRT plus memantine).
For HA‑WBRT requests, document absence of metastases within 5 mm of the hippocampus, absence of leptomeningeal disease, expected survival ≥ 4 months, and ECOG ≤ 2 or KPS ≥ 70.

Key Terms and Abbreviations

Definitive Therapy — definition of curative-intent radiation treatments

DefinitionDefinitive Therapy = radiation treatments for cancer with curative intent

ScopeApplied to IMRT when intended as primary curative treatment for the listed primary sites

Policy noteDefinition was updated in the policy history

IMRT — technical definition of intensity-modulated radiation therapy

DefinitionIMRT = computer-controlled linear accelerators modulate beam intensity to conform dose to 3D tumor volumes and spare critical structures

CapabilityAllows higher tumor dose while minimizing dose to adjacent normal tissues

Background and Scope

Intensity‑modulated radiation therapy (IMRT) is an advanced, high‑precision external beam technique that modulates beam intensity to conform dose to three‑dimensional target volumes while sparing adjacent normal tissues. IMRT planning and delivery typically incorporate image guidance (IGRT) and may be used across multiple tumor sites where conformal dose shaping reduces clinically meaningful exposure to organs at risk.

Policy Update History

2025-10-01state_specific_creationLatest

Created a state-specific policy version for North Carolina; no change to coverage guidelines.

2025-06-01coverage_rationale_revision

Revised the list of conditions considered proven and medically necessary for Definitive Therapy: added 'vulvar cancer' and replaced 'anal cancer' with 'anus/anal canal cancer'; also added language that the policy does not apply to Idaho and Kansas.

2025-06-01

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for North Carolina Only)

Policy CodePolicy CSNCT0407.04

Change TypeCoverage criteria revised (material)

Effective DateJun 1, 2025

Next Review DateN/A

SourceLink

On This Page

Denial Risk

Medical necessity documentation and documentation‑based denial risk

Medical records may be required to verify that clinical criteria for medically necessary IMRT or HA‑WBRT are met; however, providing records does not guarantee coverage. Coverage decisions remain subject to federal/state/contractual benefit terms. Missing or incomplete documentation that fails to demonstrate the clinical criteria or dosimetric justification may lead to a documentation‑based denial.

Benefit coverage is governed by federal, state, and contractual requirements; check the member’s specific benefit plan prior to authorization.
UnitedHealthcare may use third‑party tools (for example, InterQual®) to assist in benefit administration; these tools do not replace plan terms.
Failure to provide required medical records or dosimetric comparisons may result in denial of the request.

Documentation Required

Indication, IGRT, anatomic and dosimetric documentation

When IMRT is selected to reduce dose to critical OARs, include anatomic and dosimetric documentation: clearly identify the indication, tumor location and relation to adjacent OARs, distances where relevant (e.g., distance from tumor to hippocampus), target volumes, prescribed dose and fractionation, and specific OAR constraints used. Document the image‑guided radiation therapy (IGRT) technique to be used and steps to ensure reproducibility and delivery accuracy.

Required: target delineation, PTV volumes, prescription dose and fractionation, and dose‑volume histograms (DVHs) for targets and OARs.
If IMRT is requested to spare a named OAR (e.g., hippocampus, heart, stomach/duodenum), provide plan comparisons quantifying the reduction in mean or maximum dose to that OAR.
Document planned IGRT method (e.g., orthogonal imaging, cone beam CT) and verification frequency.

Prior Authorization

HA‑WBRT eligibility risk and co‑therapy documentation

HA‑WBRT eligibility: do not offer hippocampal‑avoidance WBRT to individuals with metastases within the hippocampal‑avoidance region or with leptomeningeal disease, or to individuals with an expected survival < 4 months. HA‑WBRT requests should document memantine co‑therapy when applicable, and confirm performance status and prognosis.

Document absence of metastases within 5 mm of the hippocampus and absence of leptomeningeal disease.
Expected survival ≥ 4 months and ECOG performance status ≤ 2 or KPS ≥ 70 should be recorded.
Note memantine is recommended co‑therapy based on ASCO/SNO/ASTRO guidance for patients receiving WBRT with hippocampal avoidance.

Documentation Required

Clinical rationale and guideline support

Clinical rationale and guideline support should be summarized in the request: state the diagnosis, stage, intent of RT (definitive, postoperative, palliative), prior irradiation to the same or adjacent area if applicable, and cite the supporting guideline(s) that recommend IMRT for the scenario (for example, NCCN preference for head & neck, pelvic/para‑aortic treatment; ASTRO strong recommendations for CNS gliomas and endometrial adjuvant RT).

If prior RT has been delivered to the same or adjacent area, include prior dose/fractionation and cumulative dose constraints demonstrating need for IMRT to avoid exceeding normal tissue tolerance.
For non‑listed indications, explain why a non‑IMRT approach would increase clinically meaningful normal tissue toxicity and reference relevant RTOG/QUANTEC constraints where applicable.

Note

Prior authorization — informational

Prior authorization informational note: combined IMRT plus proton plans lack evidence and may be denied. FDA device information for IMRT systems is provided for informational purposes only and is not a basis for coverage; include device product codes if relevant to the request.

Requests proposing combined IMRT and proton beam therapy in a single treatment plan may be denied due to insufficient evidence.
For informational purposes: FDA product codes MUJ and IYE pertain to IMRT devices (see FDA PMN site). FDA approval alone does not establish coverage.
Check the policy and benefit terms — device approval does not replace the medical necessity requirements in this policy.

Note

Check benefit requirements and potential use of third‑party tools

Check the member’s specific benefit requirements and applicable federal/state/contractual rules before applying this policy. UnitedHealthcare may use third‑party criteria (e.g., InterQual®) in benefit administration; these tools are supplemental and plan terms govern when conflicts exist.

Verify state‑specific policy applicability (this policy may not apply in all states; see policy history for state‑specific versions).
When in doubt, obtain pre‑authorization and supply supporting guidelines and dosimetric comparisons.